Abstract: The present disclosure relates to a fusion protein including a cell-penetrating peptide and an LRR domain derived from the NLRX1 protein. Since the fusion protein can effectively inhibit and alleviate the disease severity of autoimmune diseases and directly regulates T cell functions, it can be usefully used to treat or prevent autoimmune diseases.

Abstract: The present invention relates to pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer. More specifically, the present invention relates to compositions that enhance anti-cancer immunity of the lung rather than induce death of advanced cancer, thus being effective in inhibiting, preventing or treating pulmonary metastasis of cancer.

Abstract: A novel cytokine-derived cell penetrating peptide and use thereof are provided. The cell penetrating peptide has the ability to effectively deliver a biologically active substance into phagocytes, particularly macrophages, both in vitro and in vivo. The cell penetrating peptide can deliver a biologically active substance into macrophages with high efficiency compared to TAT peptide and dNP2 peptide that are commercially available as cell penetrating peptides.

Abstract: The composition of the present invention can inhibit homologous human T cell reaction and the phenomenon of infiltration which reduces skin graft damage in vivo, thereby enabling prompt, rapid and effective graft rejection prevention or treatment effects at a low concentration. In addition, the present invention has advantages of successfully controlling in vivo human T cell reactions, as compared with conventional therapeutic agents, thus providing few side effects, the possibilities of local high-dose administration of therapeutic agents and potentially new treatments and prescriptions.

Abstract: The present disclosure relates to a composition for enhancing the cell permeability and gene correction efficiency of Cas protein and guide RNA. The currently used CRISPR-Cas-based gene correction technology has the problems of difficult intracellular injection in a complex form, unverified stability and low efficiency even after injection, and the off-target problem. In contrast, the composition for gene correction of the present disclosure can be usefully used for gene therapy due to remarkably high intracellular delivery efficiency, inhibited off-target, and ensured stability.

Abstract: The present disclosure relates to a fusion protein including a cell-penetrating peptide and an LRR domain derived from the NLRX1 protein. Since the fusion protein can effectively inhibit and alleviate the disease severity of autoimmune diseases and directly regulates T cell functions, it can be usefully used to treat or prevent autoimmune diseases.

Abstract: The present invention has a function of enabling the penetration of the blood-brain barrier and the blood-spinal cord barrier of the central nervous system, which have not been significantly penetrated, with excellent efficiency, thereby enabling a rapid, quick, and more efficient therapeutic effect to be obtained through low dose administration. In addition, the present invention enables local administration unlike conventional therapeutic agents, thereby decreasing side effects, and enables local administration of a therapeutic agent at a high concentration, thereby enabling potentially new treatments and prescriptions.

Abstract: The present invention relates to pharmaceutical compositions for preventing or treating pulmonary metastasis of cancer. More specifically, the present invention relates to compositions that enhance anti-cancer immunity of the lung rather than induce death of advanced cancer, thus being effective in inhibiting, preventing or treating pulmonary metastasis of cancer.

Abstract: The present disclosure is directed to providing a new skin-penetrating peptide, a fusion product with a biologically active substance bound using the same, a cosmetic composition containing the same and a pharmaceutical composition for external application to skin containing the same. The skin-penetrating peptide of the present disclosure is less likely to cause an immune response as compared to existing skin-penetrating peptides and exhibits remarkably improved skin permeability. Therefore, the biologically active substance can be effectively delivered through the skin, particularly through the stratum corneum.

Abstract: A peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1: Asn-Tyr-Pro-Gln-Arg-Pro, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient are disclosed. When cancer cells are treated with the peptide and the pharmaceutical composition containing the same, the peptide can specifically bind to CP2c by passing, with very high stability, through the cell membrane and can inhibit the DNA binding ability of CP2c, thereby disturbing CP2c-mediated cancer cell-specific transcriptional activity through the inhibition of CP2c activity. Thus, the peptide and pharmaceutical composition containing the same can be effectively used for specifically treating only cancer cells and can be utilized for cancer prevention and as a dietary supplement additive therefor.

Abstract: The composition of the present invention can inhibit homologous human T cell reaction and the phenomenon of infiltration which reduces skin graft damage in vivo, thereby enabling prompt, rapid and effective graft rejection prevention or treatment effects at a low concentration. In addition, the present invention has advantages of successfully controlling in vivo human T cell reactions, as compared with conventional therapeutic agents, thus providing few side effects, the possibilities of local high-dose administration of therapeutic agents and potentially new treatments and prescriptions.

Abstract: The present disclosure relates to a pharmaceutical composition for preventing or treating an inflammatory respiratory disease, which contains a fusion protein in which a cell-penetrating peptide and a ctCTLA4 peptide are fused as an active ingredient. The present disclosure can provide quick, fast, and effective therapeutic or preventive effect for inflammatory respiratory diseases, particularly allergic asthma, via administration through the respiratory system, with which effective therapeutic or preventive effect could not be achieved, by providing superior delivery and targeting efficiency for a bronchus and lung cells and remarkably improved activities of suppressing cytokine expression, suppressing airway inflammation, alleviating airway hyperresponsiveness to allergens, alleviating Th2 inflammation, etc. as compared to the existing therapeutic agents.

Abstract: The present invention has a function of enabling the penetration of the blood-brain barrier and the blood-spinal cord barrier of the central nervous system, which have not been significantly penetrated, with excellent efficiency, thereby enabling a rapid, quick, and more efficient therapeutic effect to be obtained through low dose administration. In addition, the present invention enables local administration unlike conventional therapeutic agents, thereby decreasing side effects, and enables local administration of a therapeutic agent at a high concentration, thereby enabling potentially new treatments and prescriptions.

Abstract: The present disclosure is directed to providing a new skin-penetrating peptide, a fusion product with a biologically active substance bound using the same, a cosmetic composition containing the same and a pharmaceutical composition for external application to skin containing the same. The skin-penetrating peptide of the present disclosure is less likely to cause an immune response as compared to existing skin-penetrating peptides and exhibits remarkably improved skin permeability. Therefore, the biologically active substance can be effectively delivered through the skin, particularly through the stratum corneum.

Abstract: The present disclosure is directed to providing: a new cell-penetrating peptide; and a composition for delivering a biologically active substance, a composition for gene therapy, a method for delivering a biologically active substance and a method for gene therapy using the same. The cell-penetrating peptide of the present disclosure can effectively deliver a protein into human cells and tissues, can deliver a protein with higher efficiency in comparison with a TAT peptide that is commercially used as a cell-penetrating peptide, and can also be usefully used in delivering a biologically active substance such as a protein, a genetic material, a chemical compound, etc. which may be used for a therapeutic purpose into cells.

Abstract: The present invention relates to a peptide having an anticancer activity, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient and, more specifically, to a peptide binding to transcription factor CP2c, having an activity of preventing and treating cancer and represented by SEQ ID NO: 1, and a pharmaceutical composition and a dietary supplement composition for preventing and treating cancer, both of which contain the same as an active ingredient.

Abstract: The present disclosure is directed to providing: a new cell-penetrating peptide; and a composition for delivering a biologically active substance, a composition for gene therapy, a method for delivering a biologically active substance and a method for gene therapy using the same. The cell-penetrating peptide of the present disclosure can effectively deliver a protein into human cells and tissues, can deliver a protein with higher efficiency in comparison with a TAT peptide that is commercially used as a cell-penetrating peptide, and can also be usefully used in delivering a biologically active substance such as a protein, a genetic material, a chemical compound, etc. which may be used for a therapeutic purpose into cells.

Abstract: The present invention relates to methods for delivery of fusion polypeptides into cells. Methods are provided for local delivery of fusion polypeptides, e.g., through the skin, eye and the airway, to prevent allergic inflammation, airway hyper-responsiveness and to block T cell activation. Methods for delivery of fusion polypeptides to suppress graft rejection are also provided.

Abstract: The present invention relates to methods for delivery of fusion polypeptides into cells. Methods are provided for local delivery of fusion polypeptides, e.g., through the skin, eye and the airway, to prevent allergic inflammation, airway hyper-responsiveness and to block T cell activation. Methods for delivery of fusion polypeptides to suppress graft rejection are also provided.

Abstract: This invention relates to a method for in vivo and in vitro transferring efficiently DNA/RNA coding materials regulating bio-function to cytoplasm or nucleus in eukaryotic or prokaryotic cells using PTD (Protein Transduction Domain) and DNA/RNA binding factor. Particularly, this invention provides a method for in vivo transferring the materials to cells through various routes comprising intramuscular, intraperitoneal, intravein, oral, nasal, subcutaneous, intradermal, mucosal, inhalation. Accordingly, the method of this invention can be used for technology to transfer DNA/RNA to various cell types and express them in the cells transiently or permanently in medicinal applications such as DNA/RNA vaccine and gene therapy, as well as basic applications.